封面
市場調查報告書
商品編碼
2177782

寵物代謝健康市場預測至2034年-全球分析(按產品類型、健康狀況、寵物品種、護理環境、診斷和監測工具、專業通路和地區分類)

Pet Metabolic Health Market Forecasts to 2034 - Global Analysis By Product Category, Health Condition, Pet Type, Care Setting, Diagnostic and Monitoring Tool, Professional Channel, and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 300+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據,預計到 2026 年,全球寵物代謝健康市場規模將達到 12 億美元,並在預測期內以 7.9% 的複合年成長率成長,到 2034 年將達到 22 億美元。

該市場涵蓋糖尿病以外的代謝和內分泌疾病的診斷、治療和營養解決方案,包括內分泌藥物、實驗室檢測組合和代謝補充劑。這些產品用於支持甲狀腺疾病、血脂異常症及相關代謝性疾病的檢測和持續管理。市場成長反映了診斷服務的普及性和對綜合慢性病管理需求的不斷成長。未來的市場滲透率將取決於技術的成熟度、客戶信心、定價以及服務網路的覆蓋範圍。

人們對伴侶動物慢性代謝疾病的認知不斷提高

寵物代謝健康的需求源於識別和管理伴侶動物疾病的需要,例如糖尿病、甲狀腺功能障礙以及血脂和血糖異常。獸醫診所透過血液和尿液檢查檢測來評估代謝狀況,治療方案可能包括藥物治療、治療性飲食和定期監測。當體重變化、飲水量變化、食慾變化和嗜睡等症狀持續存在時,寵物飼主往往會尋求持續的治療。因此,診斷產品、實驗室服務和疾病特異性飲食在護理過程中發揮著相互關聯的作用。慢性疾病的管理也帶來了持續監測和治療支援的需求。

診斷難題、治療費用、飼主。

代謝性疾病難以識別,因為體重波動、口渴加劇和活動量減少等徵兆可能與其他疾病和正常老齡化重疊。診斷可能需要臨床檢查和重複測量,這不僅費用高昂,而且需要獸醫服務。治療可能包括每日服藥、注射胰島素、飲食管理和定期監測,這對飼主來說可能是一個持續的負擔。此外,貓和狗對治療的反應可能有所不同,需要調整劑量和飲食。追蹤不足會使疾病管理變得困難,而某些地區獸醫檢測實驗室的匱乏也會阻礙及時診斷。

綜合診斷、治療性營養管理和預防性獸醫護理。

協調診斷檢測、治療性營養和長期獸醫監測蘊藏著巨大的機會。即時檢測使診所能夠在就診期間評估血糖值和相關代謝指標,並可根據需要使用實驗室檢測進行更詳細的評估。對於患有糖尿病、肥胖相關代謝紊亂或血脂異常症的動物,疾病特異性飲食可以作為治療的輔助。數位化提醒和連網監測工具可以幫助飼主更好地安排用藥、餵食和檢測時間。能夠連接獸醫醫院、診斷實驗室和寵物營養供應商的機構可以提供比單一產品更全面的管理方案。

監管監督和與現有獸醫醫療的競爭

當飼主選擇一般保健食品、居家監測或延遲就診而非進行系統診斷和治療時,這些替代療法可能會與專門針對代謝健康的產品形成競爭。對居家檢測結果的錯誤解讀可能導致虛假的安心感或不必要的擔憂,而未經證實的補充劑可能會分散用於臨床合理治療的資金。診斷服務提供者也面臨現有獸醫實驗室和由動物醫院獨立運作的檢測系統的競爭。檢測方案和臨床建議的變更可能會降低某些產品的效用。企業必須確保其分析的可靠性、清晰的解讀指南以及與獸醫工作流程的兼容性,才能維護行業信任。

新型冠狀病毒(COVID-19)的影響:

新冠疫情擾亂了獸醫預約安排、寵物專賣店、旅遊業和寵物護理供應鏈,同時也促使人們更多地轉向線上購買和尋求建議。雖然一些飼主推遲了非必要的服務,但居家時間的增加和對動物健康意識的提高推動了對居家產品和數位化支援的需求。企業紛紛回應,推出了電子商務、遠距醫療和靈活的預約安排。隨著限制措施的逐步放寬,離線服務逐漸恢復,但人們對便利性和清晰產品資訊的需求仍然存在。疫情的影響因市場而異,取決於臨床需求、自由裁量權支出以及在條件允許的情況下對線下體驗的依賴程度。

在預測期內,內分泌和代謝治療領域預計將佔據最大的市場佔有率。

在預測期內,內分泌和代謝治療領域預計將佔據寵物代謝健康市場最大的佔有率。這一地位反映了該領域對目標伴侶動物群體的重要性,以及其主要產品類型的廣泛應用範圍。成熟的產品供應、飼主的熟悉度和專家推薦支撐了市場需求,而多樣化的照護需求則推動了重複購買和服務利用。預計參與企業市場的企業將透過有針對性的產品開發、拓展分銷網路和提供更清晰的使用指南來優先發展該領域。

預計在預測期內,「代謝合併症」細分市場將呈現最高的複合年成長率。

預計在預測期內,「代謝合併症」細分市場將呈現最高的複合年成長率,這主要得益於醫療服務提供者拓展其針對性解決方案,並透過獸醫診所、專科零售商和數位化管道提升服務可近性。推動市場需求成長的因素包括:人們對相關需求的認知不斷提高、產品配方和服務交付的改進,以及飼主越來越願意為寵物提供個人化照護。隨著便利性和可近性的提升,該細分市場有望吸引新的參與者,並促使現有醫療服務提供者拓展其產品組合。

市佔率最大的地區:

北美預計將佔據寵物代謝健康市場最大的佔有率,這得益於其較高的寵物擁有率、相對完善的獸醫基礎設施、成熟的寵物專賣零售商以及較高的單隻寵物消費支出。美國是主要的需求中心,這得益於其獸醫診所和線上寵物護理平台的飼主,以及種類繁多的專業產品和服務。加拿大憑藉其成熟的寵物護理生態系統和成熟的伴侶動物保健服務提供商,也為市場做出了貢獻。保險的普及、消費者意識的提高以及產品創新也促進了市場滲透,儘管滲透率會因收入、地區和獸醫服務的可及性而有所不同。

複合年成長率最高的地區:

在亞太地區,寵物代謝健康市場預計將實現強勁成長,這主要得益於寵物擁有率的提高、都市區城市化進程的加快、獸醫服務的普及以及主要市場有組織寵物零售業的發展。中國、日本、韓國、印度和澳洲的市場滲透管道各不相同,這反映了各國在購買力、獸醫基礎設施、產品監管以及數位商務角色方面的差異。人們對預防性護理意識的提高以及對高階伴侶動物產品需求的成長預計將推動市場發展。市場擴張將取決於在地化產品、專業教育以及對國家動物健康和消費者保護法規的遵守情況。

免費客製化服務:

所有購買此報告的客戶均可享受以下免費自訂選項之一:

  • 企業概況
    • 對其他市場參與者(最多 3 家公司)進行全面分析
    • 對主要公司進行SWOT分析(最多3家公司)
  • 區域細分
    • 根據客戶的興趣,我們可以提供主要國家的市場規模估算和預測,以及複合年成長率(需進行可行性評估)。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章:研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章:競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章:全球寵物代謝健康市場:依產品類型

  • 內分泌和代謝藥物
  • 代謝健康補充品
  • 臨床診斷和監測工具
  • 獸用營養補充品

第6章:全球寵物代謝健康市場:依健康狀況分類

  • 甲狀腺和內分泌疾病
  • 脂質和葡萄糖代謝
  • 肝臟和胰臟疾病
  • 代謝合併症

第7章:全球寵物代謝健康市場:依寵物類型分類

  • 狗
  • 貓
  • 其他伴侶動物

第8章:全球寵物代謝健康市場:依護理環境分類

  • 動物醫院
  • 專科內科診所
  • 在線獸藥房
  • 家庭監控計劃

第9章:全球寵物代謝健康市場:依診斷與監測工具分類

  • 血液生化檢查及內分泌檢查
  • 連續血糖監測和隨機血糖監測
  • 尿液檢查及酮體檢查
  • 縱向代謝生物標記

第10章:全球寵物代謝健康市場:依專業管道分類

  • 綜合動物醫院
  • 內分泌專科醫療機構
  • 獸醫診斷檢測實驗室
  • 獸醫專用線上藥房

第11章 全球寵物代謝健康市場:按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區(RoW)
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章:公司簡介

  • Zoetis Inc.
  • Elanco Animal Health
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Dechra Pharmaceuticals PLC
  • Ceva Sante Animale
  • Virbac
  • Vetoquinol
  • IDEXX Laboratories, Inc.
  • Antech Diagnostics
  • Hill's Pet Nutrition
  • Royal Canin
  • Nestle Purina PetCare
  • Nutramax Laboratories
  • PetMed Express, Inc.
Product Code: SMRC41446

According to Stratistics MRC, the Global Pet Metabolic Health Market is accounted for $1.2 billion in 2026 and is expected to reach $2.2 billion by 2034 growing at a CAGR of 7.9% during the forecast period. The market covers diagnostic, therapeutic and nutritional solutions for metabolic and endocrine disorders beyond diabetes, including endocrine medicines, laboratory panels, and metabolic supplements. It is used to support detection and ongoing management of thyroid, lipid and related metabolic conditions. Growth reflects greater diagnostic access and demand for integrated chronic-disease management. Further uptake will be shaped by technology readiness, customer confidence, pricing and the breadth of service networks.

Market Dynamics:

Driver:

Increasing recognition of chronic metabolic conditions in companion animals

Demand in pet metabolic health is supported by the need to identify and manage disorders such as diabetes mellitus, thyroid dysfunction and lipid or glucose abnormalities in companion animals. Veterinary clinics use blood and urine testing to assess metabolic status, while treatment plans may combine medication, therapeutic nutrition and repeat monitoring. Pet owners increasingly seek ongoing management when symptoms such as weight change, altered thirst, appetite shifts or lethargy persist. Diagnostic products, laboratory services and condition-specific diets therefore serve connected parts of the care pathway. Chronic disease management creates recurring demand for monitoring and treatment support.

Restraint:

Diagnostic gaps, treatment costs and long-term owner compliance

Metabolic disorders can be difficult to identify because signs such as weight fluctuation, increased thirst and reduced activity overlap with other illnesses or normal ageing. Diagnosis may require laboratory testing and repeat measurements, adding cost and requiring access to veterinary services. Treatment can involve daily medication, insulin administration, controlled feeding and regular monitoring, which places a continuing burden on owners. Cats and dogs may also respond differently to treatment, requiring dose or diet adjustments. Inconsistent follow-up can compromise disease control, while limited access to veterinary laboratories restricts timely diagnosis in some locations.

Opportunity:

Integrated testing, therapeutic nutrition and preventive veterinary care

An important opportunity lies in linking diagnostic testing with therapeutic nutrition and longitudinal veterinary monitoring. Point-of-care assays can help clinics assess glucose or related metabolic indicators during consultations, while laboratory panels support more detailed evaluation when required. Condition-specific diets can complement treatment for animals with diabetes, obesity-related metabolic dysfunction or lipid abnormalities. Digital reminders and connected monitoring tools may help owners maintain medication, feeding and testing schedules. Suppliers that coordinate veterinary clinics, diagnostic laboratories and pet nutrition providers can offer a more continuous management pathway than standalone products.

Threat:

Regulatory scrutiny and competition from established veterinary therapies

Alternative care approaches can compete with dedicated metabolic-health products when owners rely on general wellness foods, home monitoring or delayed veterinary visits instead of structured diagnosis and treatment. Inaccurate home test interpretation may create false reassurance or unnecessary concern, while unsubstantiated supplements can divert spending from clinically appropriate care. Diagnostic providers also face competition from established veterinary laboratories and clinic-owned testing systems. Changes in testing protocols or clinical recommendations can make some products less relevant. Companies must maintain analytical reliability, clear interpretation guidance and compatibility with veterinary workflows to sustain professional confidence.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Endocrine and Metabolic Therapeutics segment is expected to be the largest during the forecast period

The Endocrine and Metabolic Therapeutics segment is expected to account for a leading share of the pet metabolic health market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal product category applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Metabolic Comorbidities segment is expected to have the highest CAGR during the forecast period

The Metabolic Comorbidities segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the pet metabolic health market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the pet metabolic health market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Pet Metabolic Health Market include Zoetis Inc., Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health, Dechra Pharmaceuticals PLC, Ceva Sante Animale, Virbac, Vetoquinol, IDEXX Laboratories, Inc., Antech Diagnostics, Hill's Pet Nutrition, Royal Canin, Nestle Purina PetCare, Nutramax Laboratories, PetMed Express, Inc..

Key Developments:

In October 2026, Fera Pets introduced a daily soft chew formulated to support lean muscle, metabolism and body condition in dogs.

In September 2026, American Animal Hospital Association released updated canine diabetes-management guidelines covering diagnosis, insulin treatment, continuous glucose monitoring, dietary management and follow-up care.

In July 2026, Royal Canin (Mars Petcare) launched its first fresh, fully cooked veterinary diet portfolio for dogs, addressing selected gastrointestinal needs, food sensitivities and reduced appetite through veterinarian-exclusive nutrition.

Product Categories Covered:

  • Endocrine and Metabolic Therapeutics
  • Metabolic Health Supplements
  • Clinical Diagnostic and Monitoring Tools
  • Veterinary Nutrition Adjuncts

Health Conditions Covered:

  • Thyroid and Endocrine Disorders
  • Lipid and Glucose Metabolism
  • Hepatic and Pancreatic Conditions
  • Metabolic Comorbidities

Pet Types Covered:

  • Dogs
  • Cats
  • Other Companion Animals

Care Settings Covered:

  • Veterinary Hospitals
  • Specialty Internal Medicine Clinics
  • Online Veterinary Pharmacies
  • Home Monitoring Programs

Diagnostic and Monitoring Tools Covered:

  • Blood Chemistry and Endocrine Panels
  • Continuous and Spot Glucose Monitoring
  • Urine and Ketone Testing
  • Longitudinal Metabolic Biomarkers

Professional Channels Covered:

  • General Veterinary Practices
  • Specialty Endocrinology Providers
  • Veterinary Diagnostic Laboratories
  • Direct Veterinary E-Pharmacy

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for regional and country-level segments
  • Strategic recommendations for new entrants
  • Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
  • Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
  • Strategic recommendations for key business segments based on market estimations
  • Competitive landscape mapping and assessment of key industry trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Metabolic Health Market, By Product Category

  • 5.1 Endocrine and Metabolic Therapeutics
  • 5.2 Metabolic Health Supplements
  • 5.3 Clinical Diagnostic and Monitoring Tools
  • 5.4 Veterinary Nutrition Adjuncts

6 Global Pet Metabolic Health Market, By Health Condition

  • 6.1 Thyroid and Endocrine Disorders
  • 6.2 Lipid and Glucose Metabolism
  • 6.3 Hepatic and Pancreatic Conditions
  • 6.4 Metabolic Comorbidities

7 Global Pet Metabolic Health Market, By Pet Type

  • 7.1 Dogs
  • 7.2 Cats
  • 7.3 Other Companion Animals

8 Global Pet Metabolic Health Market, By Care Setting

  • 8.1 Veterinary Hospitals
  • 8.2 Specialty Internal Medicine Clinics
  • 8.3 Online Veterinary Pharmacies
  • 8.4 Home Monitoring Programs

9 Global Pet Metabolic Health Market, By Diagnostic and Monitoring Tool

  • 9.1 Blood Chemistry and Endocrine Panels
  • 9.2 Continuous and Spot Glucose Monitoring
  • 9.3 Urine and Ketone Testing
  • 9.4 Longitudinal Metabolic Biomarkers

10 Global Pet Metabolic Health Market, By Professional Channel

  • 10.1 General Veterinary Practices
  • 10.2 Specialty Endocrinology Providers
  • 10.3 Veterinary Diagnostic Laboratories
  • 10.4 Direct Veterinary E-Pharmacy

11 Global Pet Metabolic Health Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Zoetis Inc.
  • 14.2 Elanco Animal Health
  • 14.3 Merck Animal Health
  • 14.4 Boehringer Ingelheim Animal Health
  • 14.5 Dechra Pharmaceuticals PLC
  • 14.6 Ceva Sante Animale
  • 14.7 Virbac
  • 14.8 Vetoquinol
  • 14.9 IDEXX Laboratories, Inc.
  • 14.10 Antech Diagnostics
  • 14.11 Hill's Pet Nutrition
  • 14.12 Royal Canin
  • 14.13 Nestle Purina PetCare
  • 14.14 Nutramax Laboratories
  • 14.15 PetMed Express, Inc.

List of Tables

  • Table 1 Global Pet Metabolic Health Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Metabolic Health Market Outlook, By Product Category (2023-2034) ($MN)
  • Table 3 Global Pet Metabolic Health Market Outlook, By Endocrine and Metabolic Therapeutics (2023-2034) ($MN)
  • Table 4 Global Pet Metabolic Health Market Outlook, By Metabolic Health Supplements (2023-2034) ($MN)
  • Table 5 Global Pet Metabolic Health Market Outlook, By Clinical Diagnostic and Monitoring Tools (2023-2034) ($MN)
  • Table 6 Global Pet Metabolic Health Market Outlook, By Veterinary Nutrition Adjuncts (2023-2034) ($MN)
  • Table 7 Global Pet Metabolic Health Market Outlook, By Health Condition (2023-2034) ($MN)
  • Table 8 Global Pet Metabolic Health Market Outlook, By Thyroid and Endocrine Disorders (2023-2034) ($MN)
  • Table 9 Global Pet Metabolic Health Market Outlook, By Lipid and Glucose Metabolism (2023-2034) ($MN)
  • Table 10 Global Pet Metabolic Health Market Outlook, By Hepatic and Pancreatic Conditions (2023-2034) ($MN)
  • Table 11 Global Pet Metabolic Health Market Outlook, By Metabolic Comorbidities (2023-2034) ($MN)
  • Table 12 Global Pet Metabolic Health Market Outlook, By Pet Type (2023-2034) ($MN)
  • Table 13 Global Pet Metabolic Health Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 14 Global Pet Metabolic Health Market Outlook, By Cats (2023-2034) ($MN)
  • Table 15 Global Pet Metabolic Health Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 16 Global Pet Metabolic Health Market Outlook, By Care Setting (2023-2034) ($MN)
  • Table 17 Global Pet Metabolic Health Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 18 Global Pet Metabolic Health Market Outlook, By Specialty Internal Medicine Clinics (2023-2034) ($MN)
  • Table 19 Global Pet Metabolic Health Market Outlook, By Online Veterinary Pharmacies (2023-2034) ($MN)
  • Table 20 Global Pet Metabolic Health Market Outlook, By Home Monitoring Programs (2023-2034) ($MN)
  • Table 21 Global Pet Metabolic Health Market Outlook, By Diagnostic and Monitoring Tool (2023-2034) ($MN)
  • Table 22 Global Pet Metabolic Health Market Outlook, By Blood Chemistry and Endocrine Panels (2023-2034) ($MN)
  • Table 23 Global Pet Metabolic Health Market Outlook, By Continuous and Spot Glucose Monitoring (2023-2034) ($MN)
  • Table 24 Global Pet Metabolic Health Market Outlook, By Urine and Ketone Testing (2023-2034) ($MN)
  • Table 25 Global Pet Metabolic Health Market Outlook, By Longitudinal Metabolic Biomarkers (2023-2034) ($MN)
  • Table 26 Global Pet Metabolic Health Market Outlook, By Professional Channel (2023-2034) ($MN)
  • Table 27 Global Pet Metabolic Health Market Outlook, By General Veterinary Practices (2023-2034) ($MN)
  • Table 28 Global Pet Metabolic Health Market Outlook, By Specialty Endocrinology Providers (2023-2034) ($MN)
  • Table 29 Global Pet Metabolic Health Market Outlook, By Veterinary Diagnostic Laboratories (2023-2034) ($MN)
  • Table 30 Global Pet Metabolic Health Market Outlook, By Direct Veterinary E-Pharmacy (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.